Adults with obesity lose nearly 15% of body weight with glucagon/GLP-1 receptor agonist
Click Here to Manage Email Alerts
Key takeaways:
- In a phase 2 trial, adults with overweight or obesity who received BI 456906 lost 14.9% of their body weight at 46 weeks.
- Full study results will be presented in June at the ADA Scientific Sessions.
A novel glucagon/GLP-1 receptor agonist conferred nearly 15% weight loss at 46 weeks among people with overweight or obesity without type 2 diabetes, according to an industry press release.
In a phase 2 clinical trial, participants with overweight or obesity and no diagnosis of type 2 diabetes were randomly assigned to subcutaneous BI 456906 (Boehringer Ingelheim and Zealand Pharma) or placebo for 46 weeks. Dose escalation took place during the first 20 weeks of the trial with dose maintenance during the final 26 weeks. At 46 weeks, the cohort lost a mean 14.9% of their body weight using the planned maintenance dose. This weight loss met the trial’s primary endpoint.
“The distinct mode of action of BI 456906 targets multiple pathways pivotal to metabolic regulation, including those associated with obesity and liver diseases,” Carinne Brouillon, head of human pharma for Boehringer Ingelheim, said in a press release. “With our longstanding heritage in cardio-renal-metabolic diseases, we are excited by the findings and potential implications for millions of people who urgently need healthcare solutions.”
These findings follow data presented at ObesityWeek in November 2022 that revealed that compared with 1 mg semaglutide, once-weekly BI 456906 was associated with greater weight loss among adults with overweight or obesity plus type 2 diabetes. As Healio previously reported, adults with type 2 diabetes and overweight or obesity lost 8.95% of their body weight at 16 weeks with 3.6 mg of BI 456906 compared with a 5.4% weight loss for adults receiving 1 mg of semaglutide.
According to the press release, full results and an analysis of the actual maintenance dose indicating greater weight loss will be presented at the American Diabetes Association Scientific Sessions in June.
Read more about
Click Here to Manage Email Alerts